BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Cambrex Corporation (CBM) to Announce Fourth Quarter 2012 Financial Results on February 6, 2013


2/4/2013 6:19:54 AM

EAST RUTHERFORD, N.J., Feb. 1, 2013 /PRNewswire/ -- Cambrex Corporation (NYSE: CBM) announced that fourth quarter 2012 financial results will be released on Wednesday, February 6, 2013 after the market closes.

The Company will host a conference call to discuss the financial results.


Fourth Quarter 2012 Earnings Conference Call



When:

Thursday, February 7, 2013 at 8:30 a.m. Eastern Time



Dial-in:

1-800-723-6604 for U.S.


1-785-830-7977 for International


Passcode: 6398974



Dial-in Replay:

1-888-203-1112 for U.S.


1-719-457-0820 for International


Passcode: 6398974


Available through Thursday, February 14, 2013



Webcast:

www.cambrex.com

About Cambrex

Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. The Company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and formulation of finished dosage form products. For more information, please visit www.cambrex.com.

SOURCE Cambrex Corporation



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->